Literature DB >> 12885435

Effects of central hypocretin-1 administration on hemodynamic responses in young-adult and middle-aged rats.

Kazuyoshi Hirota1, Tetsuya Kushikata, Mihoko Kudo, Tsuyoshi Kudo, Darren Smart, Akitomo Matsuki.   

Abstract

The prevalence of hypertension in middle age correlates with impaired autonomic regulation and as norepinephrinergic neurons decline with increasing age, and this reduction may contribute to this impairment. Central hypocretin-activated norepinephrinergic neurons contribute to sympathetic regulation. In the present study we compared sympathoadrenal effects of intracerebroventricular (i.c.v.) hypocretin-1(5 nmol) between young-adult (12-14 weeks) and middle-aged (12-14 months) rats. Arterial blood pressure, heart rate and plasma catecholamines were assessed under pentobarbital anesthesia. In addition, we compared hypocretin-1 and K(+)-evoked norepinephrine release from the cerebrocortical slices prepared from young-adult and middle-aged rats. We also examined whether the novel hypocretin receptor-1 antagonist (SB-334867) could reverse these hypocretin-1 effects both in vivo and in vitro. I.c.v. hypocretin-1 significantly increased blood pressure by some 7%, heart rate by 9% and plasma norepinephrine concentrations by 100% in young-adult rats. In middle-aged rats these parameters did not change. Plasma epinephrine did not increase in either group. There was a significant correlation between changes in mean arterial pressure and plasma norepinephrine. Similarly, hypocretin-1 evoked norepinephrine release from cerebrocortical slices prepared from young-adult rats was significantly higher than that of middle-aged rats whilst K(+)-evoked release did not differ between the groups. SB-334867 significantly attenuated hypocretin-1-increased blood pressure and both in vivo and in vitro norepinephrine release. The present data suggest that hypocretinergic neurons may contribute to the regulation of central but not adrenal sympathetic activity. Moreover, sympathetic regulation by hypocretinergic neurones may disappear in middle-age in rats.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12885435     DOI: 10.1016/s0006-8993(03)03002-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  12 in total

Review 1.  The hypocretins/orexins: integrators of multiple physiological functions.

Authors:  Jingcheng Li; Zhian Hu; Luis de Lecea
Journal:  Br J Pharmacol       Date:  2014-01       Impact factor: 8.739

Review 2.  Respiration and autonomic regulation and orexin.

Authors:  Eugene Nattie; Aihua Li
Journal:  Prog Brain Res       Date:  2012       Impact factor: 2.453

Review 3.  Orexin/hypocretin based pharmacotherapies for the treatment of addiction: DORA or SORA?

Authors:  Shaun Yon-Seng Khoo; Robyn Mary Brown
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

Review 4.  Neuropeptides controlling energy balance: orexins and neuromedins.

Authors:  Joshua P Nixon; Catherine M Kotz; Colleen M Novak; Charles J Billington; Jennifer A Teske
Journal:  Handb Exp Pharmacol       Date:  2012

5.  Cerebrospinal fluid hypocretin (orexin) levels are elevated by play but are not raised by exercise and its associated heart rate, blood pressure, respiration or body temperature changes.

Authors:  M-F Wu; R Nienhuis; N Maidment; H A Lam; J M Siegel
Journal:  Arch Ital Biol       Date:  2011-11-07       Impact factor: 1.000

6.  Neuroendocrine, Autonomic, and Metabolic Responses to an Orexin Antagonist, Suvorexant, in Psychiatric Patients with Insomnia.

Authors:  Masaru Nakamura; Takahiko Nagamine
Journal:  Innov Clin Neurosci       Date:  2017-04-01

Review 7.  Role of Orexin-A in Hypertension and Obesity.

Authors:  Roberta Imperatore; Letizia Palomba; Luigia Cristino
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

Review 8.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

9.  Orexin receptors in GtoPdb v.2021.3.

Authors:  Paul Coleman; Luis de Lecea; Anthony Gotter; Jim Hagan; Daniel Hoyer; Thomas Kilduff; Jyrki P Kukkonen; Rod Porter; John Renger; Jerome M Siegel; Gregor Sutcliffe; Neil Upton; Christopher J Winrow
Journal:  IUPHAR BPS Guide Pharm CITE       Date:  2021-09-02

10.  Is neurotransmitter release involved in the mechanism of general anesthesia?

Authors:  Kazuyoshi Hirota; Tetsuya Kushikata; Daiki Takekawa; Mihoko Kudo
Journal:  J Anesth       Date:  2019-12-02       Impact factor: 2.078

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.